Referencias bibliográficas

    1. Amini, M., Zayeri, F., Salehi, M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC public health, 2021, 21, 1-12.
    2. https://www.ine.es/dyngs/Prensa/pEDCM2023.htm#:~:text=A%20nivel%20m%C3%A1s%20detallado%2C%20entre,4%25%20menos%20que%20en%202022.
    3. Umer, A., Kelley, G. A., Cottrell, L. E., Giacobbi, P., Innes, K. E., Lilly, C. L. Childhood obesity and adult cardiovascular disease risk factors: a systematic review with meta-analysis. BMC public health, 2017, 17, 1-24.
    4. Nabel, E. G. Cardiovascular disease. New England Journal of Medicine, 2003, 349 (1), 60-72.
    5. Brieler, J. A. Y., Breeden, M. A., Tucker, J.  Cardiomyopathy: an overview. American family physician, 2017, 96 (10), 640-646.
    6. Lahoz, C., Mostaza, J.M. La Aterosclerosis como enfermedad sistémica, Revista Española de Cardiología, 2007, 60 (2),184-195
    7. Custodio-Chablé S.J, Lezama R.A, Reyes-Maldonado E. Platelet activation as a trigger factor for inflammation and aterosclerosis, Cir Cir. 2020, 88 (2), 233-243.
    8. Kakadiya, J. Causes, symptoms, pathophysiology and diagnosis of atherosclerosis–a review. PharmacologyOnline, 2009, 3, 420-442.
    9. Grysiewicz, R. A., Thomas, K., Pandey, D. K. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors, Neurologic clinics, 2008, 26 (4), 871-895.
    10. Brouwers, S., Sudano, I., Kokubo, Y., Sulaica, E. M. Arterial hypertension. The Lancet, 2021, 398 (10296), 249-261.
    11. Grover-Páez, F., Zavalza-Gómez, A. B. Endothelial dysfunction and cardiovascular risk factors. Diabetes research and clinical practice, 2009, 84 (1), 1-10.
    12. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int. J. Prev. Med. 2014, 5 (8), 927-946.
    13. El-Saber Batiha G. et al. Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review. Nutrients. 2020, 12 (3), 872.
    14. Koscielny J., Klüßendorf D., Latza R., Schmitt R., Radtke K., Siegel G., Kiesewetter H. The antiatherosclerotic effect of Allium sativum, Atherosclerosis, 1999, 144 (1), 237-249.
    15. Efentakis P. et al. Effects of the olive tree leaf constituents on myocardial oxidative damage and atherosclerosis. Planta Med. 2015, 81 (8), 648-654.
    16. Gonzalez-Santiago M. et al. One month administration of hydroxytyrosol, a phenolic anti-oxidant present in olive oil, to hyperlipemic rabbits inproves blood lipid profile, anti-oxidant status and reduces atherosclerosis development. Atherosclerosis 2006; 188: 35-42.
    17. Weng Y. et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. Int. J. Mol. Sci. 2017, 18 (3), 523.
    18. Ren NN, Chen HJ, Li Y, Mcgowan GW, Lin YG. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi. 2017, 97 (26), 2038-2042.
    19. Suárez-Rivero J.M, Pastor-Maldonado C.J, de la Mata, M. et al. Atherosclerosis and Coenzyme Q10. Int J Mol Sci. 2019, 20 (20), 5195.
    20. Pepe, S., Marasco, S. F., Haas, S. J., Sheeran, F. L., Krum, H., Rosenfeldt, F. L. Coenzyme Q10 in cardiovascular disease. Mitochondrion, 2007, 7, S154-S167.
    21. Benstoem, C., Goetzenich, A., Kraemer, S., Borosch, S., Manzanares, W., Hardy, G., & Stoppe, C. Selenium and its supplementation in cardiovascular disease—what do we know?. Nutrients, 2015, 7 (5), 3094-3118.
    22. Alehagen U., Johansson P., Björnstedt M., Rosén A., Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013, 167 (5), 1860-1866.